<DOC>
	<DOCNO>NCT00052598</DOCNO>
	<brief_summary>This phase I/II trial study side effect give therapeutic allogeneic lymphocytes together aldesleukin see well work treat patient high-risk recurrent myeloid leukemia undergo donor stem cell transplant . Biological therapy , therapeutic autologous lymphocyte , may stimulate immune system different way stop cancer cell grow . Aldesleukin may stimulate white blood cell kill cancer cell . Giving therapeutic autologous lymphocytes together aldesleukin may kill cancer cell</brief_summary>
	<brief_title>Therapeutic Allogeneic Lymphocytes Aldesleukin Treating Patients With High-Risk Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety potential toxicity associate infuse donor CD8+ cytotoxic T lymphocytes ( CTL ) clone specific Proteinase 3 ( Myeloblastin ) patient relapse/progression high risk myeloid leukemia transplant . SECONDARY OBJECTIVES : I . To determine vivo persistence transfer T cell assess migration bone marrow , predominant site leukemic relapse . II . To determine adoptively transferred proteinase 3 ( PR3 ) -specific T cell mediate antileukemic activity . OUTLINE : Patients receive allogeneic CD8+ PR3-specific CTLs intravenously ( IV ) 1-2 hour day 0 , 7 , 14 , 28 , 49 aldesleukin subcutaneously ( SC ) twice daily day 28-41 49-63 absence unacceptable toxicity . After completion study treatment , patient follow every 1-3 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Patients undergo allogeneic hematopoietic stem cell transplantation chronic myelogenous leukemia ( CML ) accelerate blast phase , acute myeloid leukemia ( AML ) beyond first remission , primary refractory AML , therapyrelated AML stage , acute leukemia stage arise patient antecedent diagnosis myelodysplastic myeloproliferative syndrome ( include chronic myelomonocytic leukemia , CML , polycythemia vera , essential thrombocytosis , agnogenic myeloid metaplasia myelofibrosis ) Patients donor must human leukocyte antigen ( HLA ) A2 positive Patients must able provide blood bone marrow sample require protocol Eligibility Prophylactic Treatment CD8+ CTL After Transplant ( Highest Risk Subgroup ) : At time plan treatment , CD8+ CTL specific PR3 must generate complete Quality Control ( QC ) test Patients must &gt; 5 % morphologic blast detectable bone marrow peripheral blood prior time transplant Patients must evidence posttransplant recovery normal hematopoiesis ( absolute neutrophil count [ ANC ] &gt; 500/mm^3 ) least 7 day prior initiation CTL infusion Patients immunosuppressive therapy graftversushost disease ( GVHD ) eligible treatment receive corticosteroid dose corticosteroid taper &lt; equivalent 0.5 mg/kg/day prednisone ; The patient 's symptom remain stable unlikely increase stage III IV acute GVHD chronic GVHD unlikely progress follow change immunosuppressive therapy , appropriate monitoring period , deem patient treat physician principal investigator Eligibility Treatment CD8+ CTL Time Relapse After Transplant ( All Others ) : At time plan treatment , CD8+ CTL specific PR3 must generate complete Quality Control ( QC ) test Patients must evidence recurrent/progressive disease posttransplant Morphologic relapse define one following : abnormal peripheral blast absence growth factor therapy , abnormal bone marrow blast &gt; 5 % nucleated cell , extramedullary chloroma granulocytic sarcoma Flow cytometric relapse define appearance peripheral blood bone marrow cell abnormal immunophenotype detect flow cytometry consistent leukemia recurrence/progression Cytogenetic relapse/progression define appearance one metaphases bone marrow peripheral blood cell either nonconstitutional cytogenetic abnormality identify least one cytogenetic study perform prior transplant new abnormality know associated leukemia ; ( CML ) , increase number Ph+ metaphases bone marrow peripheral blood two consecutive sample engraftment , increase percentage BCR/ABL+ cell fluorescence situ hybridization ( FISH ) two consecutive sample engraftment Molecular relapse/progression define polymerase chain reaction ( PCR ) assay bone marrow ( BM ) peripheral blood mononuclear cell ( PBMC ) positive presence BCR/ABL messenger ribonucleic acid ( mRNA ) fusion transcript quantitatively increase great one order magnitude subsequent sample Patients immunosuppressive therapy GVHD time relapse eligible treatment receive corticosteroid dose corticosteroid taper &lt; equivalent 0.5 mg/kg/day prednisone ; patient 's symptom remain stable unlikely increase stage III IV acute GVHD chronic GVHD unlikely progress follow change immunosuppressive therapy , appropriate monitoring period , deem patient 's treat physician principal investigator Exclusions Treatment Time Relapse/Progression After Transplant : Patients CD8+ CTL clone specific PR3 generate time disease relapse/progression posttransplant ; patient potentially treat later CTL become available ; patient whose malignant cell overexpress PR3 , base direct analysis bone marrow sample &gt; 50 % blast leukemia cell isolated expression analysis ; either case , patient informed availability treatment protocol might eligible Patients Karnofsky performance status Lansky play score = &lt; 30 % Patients current stage III IV GVHD unresponsive therapy require therapy antiCD3 mAb , prednisone &gt; 0.5 mg/kg/day ( corticosteroid equivalent ) , treatment result ablation inactivation T cell ( antiT cell monoclonal antibody ) ; although concurrent use cyclosporine , FK506 , mycophenolate mofetil ( MMF ) strictly exclusion criterion , attempt make discontinue possible Patients require concurrent therapy hydroxyurea agent may interfere function survival infuse CTL clone Patients preexist nonhematopoietic organ toxicity deem principal investigator place patient unacceptable risk treatment protocol Patients graft rejection failure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>